Pemetrexed: Difference between revisions
From WikiMD's Wellness Encyclopedia
CSV import |
No edit summary |
||
| (2 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
[[File:Pemetrexed.svg|Pemetrexed|thumb]] | |||
[[File:Pemetrexed ball-and-stick.png|Pemetrexed ball-and-stick model|thumb]] | |||
[[File:Pathway of tetrahydrofolate and antimetabolites.pdf|Pathway of tetrahydrofolate and antimetabolites|thumb]] | |||
{{intro}} | {{intro}} | ||
Pemetrexed is a parenterally administered folate antagonist and antineoplastic agent, used in the [[treatment]] of non-small cell lung cancer and malignant [[mesothelioma]]. | Pemetrexed is a parenterally administered folate antagonist and antineoplastic agent, used in the [[treatment]] of non-small cell lung cancer and malignant [[mesothelioma]]. | ||
{{livtox}} | {{livtox}} | ||
Pemetrexed therapy has been associated with moderate rates of serum enzyme elevations during therapy, but has not been convincingly linked to instances of acute, clinically apparent [[liver injury]]. | Pemetrexed therapy has been associated with moderate rates of serum enzyme elevations during therapy, but has not been convincingly linked to instances of acute, clinically apparent [[liver injury]]. | ||
{{moa}} | {{moa}} | ||
Pemetrexed (pem" e trex' ed) is a folic acid analog which acts as an antagonist to the enzymes involved in folate dependent synthetic pathways such as thymidine synthase, dihydrofolate reductase and glycinamide ribonucleotide formyltransferase. Inhibition of these enzymes leads to decrease in intracellular thymidine and purine which interferes with [[DNA]] synthesis and leads to apoptotic cell death in rapidly dividing cells. In vitro and in vivo studies have shown that pemetrexed inhibits growth of [[mesothelioma]] and non-small cell lung cancer cell lines, and clinical trials in advanced forms of these cancers have shown improvements in overall survival times in pemetrexed treated subjects. | Pemetrexed (pem" e trex' ed) is a folic acid analog which acts as an antagonist to the enzymes involved in folate dependent synthetic pathways such as thymidine synthase, dihydrofolate reductase and glycinamide ribonucleotide formyltransferase. Inhibition of these enzymes leads to decrease in intracellular thymidine and purine which interferes with [[DNA]] synthesis and leads to apoptotic cell death in rapidly dividing cells. In vitro and in vivo studies have shown that pemetrexed inhibits growth of [[mesothelioma]] and non-small cell lung cancer cell lines, and clinical trials in advanced forms of these cancers have shown improvements in overall survival times in pemetrexed treated subjects. | ||
{{fda}} | {{fda}} | ||
Pemetrexed was approved for use in the United States in 2004. Current indications are for locally advanced or metastatic nonsquamous, non-small cell lung cancer (NSCLC) and for malignant pleural [[mesothelioma]], usually in combination with other [[antineoplastic agents]] (such as cisplatin) and with folic acid and vitamin B12 supplementation. | Pemetrexed was approved for use in the United States in 2004. Current indications are for locally advanced or metastatic nonsquamous, non-small cell lung cancer (NSCLC) and for malignant pleural [[mesothelioma]], usually in combination with other [[antineoplastic agents]] (such as cisplatin) and with folic acid and vitamin B12 supplementation. | ||
{{dose}} | {{dose}} | ||
Pemetrexed is available in single use vials of 100 or 500 mg as a powder for reconstitution under the brand name Alimta. The recommended dose is 500 mg/m2 intravenously on day 1 of each 21 day cycle. | Pemetrexed is available in single use vials of 100 or 500 mg as a powder for reconstitution under the brand name Alimta. The recommended dose is 500 mg/m2 intravenously on day 1 of each 21 day cycle. | ||
{{se}} | {{se}} | ||
Pemetrexed shares common [[side effects]] with other folate antagonists such as [[fatigue]], [[nausea]], [[vomiting]], [[anorexia]], [[diarrhea]], [[alopecia]], [[bone marrow suppression]], and rash. | Pemetrexed shares common [[side effects]] with other folate antagonists such as [[fatigue]], [[nausea]], [[vomiting]], [[anorexia]], [[diarrhea]], [[alopecia]], [[bone marrow suppression]], and rash. | ||
Uncommon, but potentially serious adverse events include febrile [[neutropenia]], infections, dehydration, renal failure, arrhythmias and peripheral neuropathy. | Uncommon, but potentially serious adverse events include febrile [[neutropenia]], infections, dehydration, renal failure, arrhythmias and peripheral neuropathy. | ||
{{coststubd}} | {{coststubd}} | ||
{{Chemotherapeutic agents}} | |||
{{Purinergics}} | |||
{{Eli Lilly and Company}} | |||
{{Portal bar | Medicine}} | |||
[[Category:Mammalian dihydrofolate reductase inhibitors]] | |||
[[Category:Drugs developed by Eli Lilly and Company]] | |||
[[Category:Pyrrolopyrimidines]] | |||
[[Category:Benzamides]] | |||
[[Category:Antifolates]] | |||
[[Category:Thymidylate synthase inhibitors]] | |||
[[Category:Purines]] | |||
{{Chemotherapeutic agents}} | |||
{{Purinergics}} | |||
{{Eli Lilly and Company}} | |||
{{Portal bar | Medicine}} | |||
[[Category:Mammalian dihydrofolate reductase inhibitors]] | |||
[[Category:Drugs developed by Eli Lilly and Company]] | |||
[[Category:Pyrrolopyrimidines]] | |||
[[Category:Benzamides]] | |||
[[Category:Antifolates]] | |||
[[Category:Thymidylate synthase inhibitors]] | |||
[[Category:Purines]] | |||
Latest revision as of 03:02, 22 March 2025
File:Pathway of tetrahydrofolate and antimetabolites.pdf
Information about Pemetrexed[edit]
Pemetrexed is a parenterally administered folate antagonist and antineoplastic agent, used in the treatment of non-small cell lung cancer and malignant mesothelioma.
Liver safety of Pemetrexed[edit]
Pemetrexed therapy has been associated with moderate rates of serum enzyme elevations during therapy, but has not been convincingly linked to instances of acute, clinically apparent liver injury.
Mechanism of action of Pemetrexed[edit]
Pemetrexed (pem" e trex' ed) is a folic acid analog which acts as an antagonist to the enzymes involved in folate dependent synthetic pathways such as thymidine synthase, dihydrofolate reductase and glycinamide ribonucleotide formyltransferase. Inhibition of these enzymes leads to decrease in intracellular thymidine and purine which interferes with DNA synthesis and leads to apoptotic cell death in rapidly dividing cells. In vitro and in vivo studies have shown that pemetrexed inhibits growth of mesothelioma and non-small cell lung cancer cell lines, and clinical trials in advanced forms of these cancers have shown improvements in overall survival times in pemetrexed treated subjects.
FDA approval information for Pemetrexed[edit]
Pemetrexed was approved for use in the United States in 2004. Current indications are for locally advanced or metastatic nonsquamous, non-small cell lung cancer (NSCLC) and for malignant pleural mesothelioma, usually in combination with other antineoplastic agents (such as cisplatin) and with folic acid and vitamin B12 supplementation.
Dosage and administration for Pemetrexed[edit]
Pemetrexed is available in single use vials of 100 or 500 mg as a powder for reconstitution under the brand name Alimta. The recommended dose is 500 mg/m2 intravenously on day 1 of each 21 day cycle.
Side effects of Pemetrexed[edit]
Pemetrexed shares common side effects with other folate antagonists such as fatigue, nausea, vomiting, anorexia, diarrhea, alopecia, bone marrow suppression, and rash. Uncommon, but potentially serious adverse events include febrile neutropenia, infections, dehydration, renal failure, arrhythmias and peripheral neuropathy.
| Purine receptor modulators | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
See also: Receptor/signaling modulators
|
| Eli Lilly and Company | ||||
|---|---|---|---|---|
|
| Intracellular chemotherapeutic agents / antineoplastic agents (L01) | ||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
| Purine receptor modulators | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
See also: Receptor/signaling modulators
|
| Eli Lilly and Company | ||||
|---|---|---|---|---|
|
